source
- Capricor sues Nippon Shinyaku over pricing dispute for Duchenne cell therapy candidateCapricor Therapeutics announced it has filed a lawsuit against its Japanese partner Nippon Shinyaku. The suit alleges a flaw in the pricing terms of the distribution and commercialization agreemen…
- Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1 billion, adding three rare-neurology drugsAngelini Pharma announced a $4.1 billion acquisition of Catalyst Pharmaceuticals, a U.S. company that develops treatments for rare neurological disorders. The purchase adds three FDA‑approved medi…